Cullinan Therapeutics, Inc. (CGEM) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 8 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CGEM is $30.43, representing a +112.1% upside from the current price of $14.35. Price targets range from a low of $26.00 to a high of $38.00.
